Metabolomic Signatures in Pediatric Crohn's Disease Patients with Mild or Quiescent Disease Treated with Partial Enteral Nutrition: A Feasibility Study.
enteral nutrition
inflammatory markers
pediatric inflammatory bowel disease
untargeted metabolomics
xenobiotics
Journal
SLAS technology
ISSN: 2472-6311
Titre abrégé: SLAS Technol
Pays: United States
ID NLM: 101697564
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
pubmed:
20
11
2020
medline:
15
12
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
Little is known about the metabolic response of pediatric Crohn's disease (CD) patients to partial enteral nutrition (PEN) therapy and the impact of disease activity and inflammation. We analyzed plasma samples from a nonrandomized controlled intervention study investigating the effect of partial enteral nutrition (PEN) on bone health and growth throughout one year with untargeted metabolomics using high-performance liquid chromatography (HPLC) coupled with high-resolution mass spectrometry (HRMS). Thirty-four paired samples from two time points (baseline and 12 months) were analyzed. Patients (median age: 13.9 years, range: 7-18.9 years, 44% females) were in remission or had mild disease activity. The intervention group received a casein-based formula for 12 months, providing ~25% of estimated daily energy requirements. Sparse partial least squares discriminant analysis (splsda) was applied for group discrimination and identifying sources of variation to identify the impact of PEN. We also investigated the correlation of metabolites with inflammation markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal calprotectin. After 12 months, our results show substantial difference between PEN and non-PEN groups in the metabolome of CD patients in remission or with mild disease activity. Inflammatory markers were associated with individual compounds and chemical classes such as isoprenoids and phospholipids. Identified compounds comprise metabolites produced by human or bacterial metabolism, as well as xenobiotics recognized as flavoring agents and environmental contaminants and their biotransformation products. Further longitudinal studies that also include patients with higher disease activity are warranted to evaluate the suitability of these metabolic biomarkers for predicting disease activity.
Identifiants
pubmed: 33207993
doi: 10.1177/2472630320969147
pmc: PMC7985853
doi:
Types de publication
Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165-177Références
Int J Biochem Cell Biol. 2012 Nov;44(11):1839-46
pubmed: 22728312
Gut. 1996 Apr;38(4):543-8
pubmed: 8707085
Nutrients. 2019 May 07;11(5):
pubmed: 31067701
Gastroenterol Clin North Am. 2017 Dec;46(4):745-767
pubmed: 29173519
IARC Monogr Eval Carcinog Risks Hum. 2013;101:9-549
pubmed: 24772663
J Nat Med. 2019 Jan;73(1):124-130
pubmed: 30324332
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):e25-e27
pubmed: 27741061
Nutrients. 2019 Sep 14;11(9):
pubmed: 31540038
Free Radic Res. 2005 Dec;39(12):1359-66
pubmed: 16298866
Analyst. 2018 Sep 24;143(19):4526-4536
pubmed: 30128447
Gastroenterology. 1988 Mar;94(3):603-10
pubmed: 3123302
Anal Biochem. 2000 Mar 15;279(2):125-9
pubmed: 10706780
Molecules. 2019 Jan 27;24(3):
pubmed: 30691236
Planta Med. 2012 Dec;78(18):1906-11
pubmed: 23115019
J Neuroimmunol. 2004 Nov;156(1-2):146-52
pubmed: 15465605
Med Hypotheses. 2002 Aug;59(2):159-63
pubmed: 12208202
Front Bioeng Biotechnol. 2015 Mar 05;3:23
pubmed: 25798438
Aliment Pharmacol Ther. 2006 Nov 1;24(9):1333-40
pubmed: 17059514
Inflamm Bowel Dis. 2009 Nov;15(11):1705-20
pubmed: 19504612
Food Chem Toxicol. 2013 Aug;58:467-78
pubmed: 23712097
Am J Physiol Gastrointest Liver Physiol. 2005 Mar;288(3):G422-30
pubmed: 15701621
Clin Gastroenterol Hepatol. 2021 Mar;19(3):425-435.e3
pubmed: 31812656
J Immunol. 2010 Dec 1;185(11):6960-73
pubmed: 21041721
Scand J Clin Lab Invest. 1999 Jul;59(4):279-87
pubmed: 10463466
Hawaii J Med Public Health. 2016 Nov;75(11):353-359
pubmed: 27920947
Front Cell Neurosci. 2014 Aug 01;8:195
pubmed: 25136293
Inflamm Bowel Dis. 2012 Jan;18(1):55-62
pubmed: 21351206
J Bacteriol. 2001 Sep;183(18):5358-63
pubmed: 11514520
Am J Gastroenterol. 2015 Dec;110(12):1718-29; quiz 1730
pubmed: 26526081
Clin Nutr. 2020 Dec;39(12):3786-3796
pubmed: 32376096
World J Gastroenterol. 2019 Mar 14;25(10):1266-1277
pubmed: 30886509
Eur J Clin Nutr. 2016 Sep;70(9):1052-6
pubmed: 27167669
Metabolomics. 2018 Jan;14(1):17
pubmed: 29681789
Int J Colorectal Dis. 2016 Jan;31(1):1-7
pubmed: 26272197
Nat Genet. 2008 Aug;40(8):955-62
pubmed: 18587394
Brief Bioinform. 2007 Sep;8(5):279-93
pubmed: 17626065
Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):263-9
pubmed: 22436749
Lancet. 1983 Apr 23;1(8330):887-90
pubmed: 6132218
Digestion. 1991;50(3-4):135-41
pubmed: 1812040
Nat Microbiol. 2019 Feb;4(2):293-305
pubmed: 30531976
BMC Bioinformatics. 2012 Dec 06;13:325
pubmed: 23216942
Pharmacol Ther. 2006 Oct;112(1):171-83
pubmed: 16759708
Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6
pubmed: 17202168
Metabolomics. 2016;12(10):149
pubmed: 27642271
Anal Bioanal Chem. 2007 Sep;389(1):119-37
pubmed: 17673989
Inflamm Bowel Dis. 2019 Jun 18;25(7):1120-1128
pubmed: 30772902
Biomed Rep. 2016 Oct;5(4):403-407
pubmed: 27699005
Lancet. 2017 Sep 23;390(10101):1486
pubmed: 28952445
World J Gastroenterol. 2012 Apr 21;18(15):1708-22
pubmed: 22553395
Inflamm Bowel Dis. 2014 May;20(5):861-71
pubmed: 24651582
Pathol Biol (Paris). 2013 Oct;61(5):e65-9
pubmed: 20381273
J Gastroenterol. 2012 Feb;47(2):107-17
pubmed: 21953313
Anal Chim Acta. 2007 Mar 7;585(2):323-30
pubmed: 17386681
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005984
pubmed: 17636816
J Chin Med Assoc. 2014 Aug;77(8):443-5
pubmed: 25028287
Gut. 2006 Mar;55(3):426-31
pubmed: 16474109
Ann Nutr Metab. 2015;66(4):219-23
pubmed: 26087853
Biochim Biophys Acta. 2006 Dec;1758(12):1864-84
pubmed: 17052686